Wanbangde: It is expected that the net profit in the first quarter of 2026 will increase by 985.40% year-on-year.

Wanbangde announcement, it is expected that the net profit attributable to shareholders of the listed company in the first quarter of 2026 will be 165 million yuan, an increase of 985.40% year-on-year; the net profit after deducting non-recurring gains and losses will be 164 million yuan, an increase of 2,174.55% year-on-year. The company's transformation from generic drugs to innovative drugs strategy is beginning to show initial results, and business expansion during the reporting period has made positive progress, bringing new growth points and continuously increasing research and development efforts. During the reporting period, the company strengthened internal management, increased efforts to recover receivables, and effectively accelerated the inflow of funds.